Skip to main content
. Author manuscript; available in PMC: 2013 Sep 13.
Published in final edited form as: Curr Med Res Opin. 2011 Oct 27;27(12):2309–2320. doi: 10.1185/03007995.2011.628648

Table 3.

Change from baseline to Visit 14 (end of double-blind phase) in drinks per day and AISRS total score stratified by baseline duration of sobriety.

Baseline Duration of Sobriety
Compare Sobriety. Group (p-value)
≤4 consecutive days >4 consecutive days

ATX (n = 17) Placebo (n = 23) Total (n = 40) ATX (n = 15) Placebo (n = 25) Total (n = 40)
Drinks per day Baseline Mean (SD) 2.25 (1.31) 3.29 (2.51) 2.85 (2.13) 1.97 (1.23) 1.93 (1.45) 1.94 (1.36) 0.0566
Drinks per day Change from baseline to V14 Mean(SD) 0.41 (2.51) 0.49 (2.55) 0.45 (2.49) 0.19 (1.66) 0.71 (2.01) 0.51 (1.88) 0.6602
AISRS, Baseline Mean (SD) 39.65 (7.01) 40.43 (7.79) 40.10 (7.38) 38.93 (9.12) 39.12 (7.08) 39.05 (7.79) 0.4221
AISRS, Change from baseline to V14 Mean (SD) −20.53 (11.32) −12.70 (13.67) −16.03 (13.16) −13.27 (11.04) −6.44 (10.02) −9.00 (10.80) 0.0790
ASRS, Baseline Mean (SD) 44.47 (8.59) 49.04 (9.14) 47.10 (9.09) 50.60 (8.35) 51.16 (9.39) 50.95 (8.91) 0.0781
ASRS, Change from baseline to V14 Mean (SD) −17.35 (9.43) −12.78 (16.21) −14.73 (13.78) −17.00 (13.85) −7.64 (11.51) −11.00 (13.04) 0.5821

ADHD – attention-deficit/hyperactivity disorder; AISRS – Adult ADHD Investigator Symptom Rating Scale; ATX – atomoxetine; SD – standard deviation; V14–Visit 14.